Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL771186 | 0.92 | MAPT (0.66) | RAB9AMAPTNPC1POLBHPGD | |
| SCHEMBL12893939 | 0.90 | RAB9A (0.57) | RAB9AMAPTNPC1POLBHPGD | |
| SCHEMBL12919546 | 0.87 | ALDH1A1 (0.55) | RAB9AMAPTNPC1POLBHPGD | |
| SCHEMBL12893938 | 0.84 | ALDH1A1 (0.52) | RAB9AMAPTNPC1POLBHPGD | |
| SCHEMBL31572050 | 0.83 | ALDH1A1 (0.56) | RAB9AMAPTNPC1HPGDHTT | |
| SCHEMBL5121082 | 0.82 | MAPT (0.55) | RAB9AMAPTNPC1POLBHPGD | |
| SCHEMBL14467294 | 0.81 | ALDH1A1 (0.66) | RAB9AMAPTNPC1ABL1HTT | |
| SCHEMBL3976332 | 0.80 | MAPT (0.90) | RAB9AMAPTNPC1POLBABL1 | |
| SCHEMBL12124929 | 0.79 | RAB9A (0.69) | RAB9AMAPTNPC1POLBHPGD | |
| SCHEMBL1542815 | 0.79 | HCAR3 (0.61) | RAB9AMAPTNPC1POLBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227765-A1 | PYRIDO-INDOLE ANALOGUES AS GPX4 INHIBITORS | ADRENAS THERAPEUTICS INC. | 2022-07-21 | — | — | US | disclosed |
| WO-2021041539-A2 | COMPOUNDS AND METHODS OF USE | Ferro Therapeutics, Inc. (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021041539-A2 | COMPOUNDS AND METHODS OF USE | Ferro Therapeutics, Inc. (US) | 2021-03-04 | — | — | WO | disclosed |
| US-8273773-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2307372-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2012-04-25 | — | — | EP | disclosed |
| EP-2307372-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010010017-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-28 | — | — | WO | disclosed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227765-A1 | PYRIDO-INDOLE ANALOGUES AS GPX4 INHIBITORS | GPX4, GPX1, AIFM2 | RAB9A 4212/4885MAPT 3709/4885NPC1 2896/4885 |
| US-20100021423-A1 | Heterocyclic antiviral compounds | POLR2A, RRM2B, RRP1B | RAB9A 203/4885MAPT 4356/4885NPC1 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.